Dr. Reddy’s Laboratories shares gained on Wednesday after it launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL, for Subcutaneous Use, a therapeutic equivalent generic version of IMITREX STATdose Pen® (sumatriptan succinate) 6 mg/0.5 mL in the US market on Feb. 25, 2014, following the approval by the United States Food & Drug Administration (USFDA).

The IMITREX STATdose Pen® (sumatriptan succinate) brand and generic combined had U.S. sales of approximately $169 million MAT for the most recent twelve months ending in December 2013 according to IMS Health.

Shares of the company are trading at Rs 2,800.00, up Rs 26.1, or 0.94% at the Bombay Stock Exchange (BSE) on Wednesday at 10:14 a.m.

The scrip has touched an intra-day high of Rs 2,823.00 and low of Rs 2,785.90. The total volume of shares traded at the BSE is 6,480.

In the earlier session, the shares fell 0.76%, or Rs 21.25, at Rs 2,773.90.

Currently, the stock is trading down 0.53% from its 52-week high of Rs 2,815.00 and above 62.74% over the 52-week low of Rs 1,720.50.